Previous Article | Next Article ![]()
J Virol, July 1998, p. 6151-6154, Vol. 72, No. 7
Departments of
Medicine1 and
Microbiology and
Immunology,2
University of Rochester
School of Medicine and Dentistry, Rochester, New York 14642; MedImmune,
Inc., Gaithersburg, Maryland 208783; and
Section of Pediatric Hematology/Oncology, University of
Colorado School of Medicine, Denver, Colorado 802624
Received 7 January 1998/Accepted 27 March 1998
The human papillomavirus type 11 (HPV-11) L1 major capsid protein
can be trypsinized to generate recombinant capsomeres that retain HPV
genotype-restricted capsid antigenicity (M. Li, T. P. Cripe,
P. A. Estes, M. K. Lyon, R. C. Rose, and R. L. Garcea, J. Virol. 71:2988-2995, 1997). In the present study,
HPV-11 virion-neutralizing monoclonal antibodies H11.F1 and H11.H3,
previously characterized as recognizing two distinct HPV-11
capsid-neutralizing antigenic domains (S. W. Ludmerer, D. Benincasa, and G. E. Mark III, J. Virol. 70:4791-4794,
1996), were each found to be highly immunoreactive with
trypsin-generated capsomeres in an enzyme-linked immunosorbent assay
(ELISA). Capsomeres were used to generate high-titer polyclonal immune
sera that demonstrated HPV genotype-restricted reactivity by ELISA. The
capsomere antisera were then tested in an in vitro infectivity assay
and found to neutralize HPV-11 virions. In this assay, HPV-11 capsomere
polyclonal antisera exhibited neutralization titers (10
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Human Papillomavirus Type 11 Recombinant L1
Capsomeres Induce Virus-Neutralizing Antibodies
5
to 10
6) comparable to those obtained with a
virion-neutralizing antiserum raised previously against intact HPV-11
VLPs (R. C. Rose, R. C. Reichman, and W. Bonnez, J. Gen.
Virol. 75:2075-2079, 1994). These results indicate that highly
immunogenic, genotype-restricted HPV capsid-neutralizing antigenic
domains are contained entirely within capsomeres. Thus, capsomeres may
be viable vaccine candidates for the prevention of HPV disease.
*
Corresponding author. Mailing address: University of
Rochester School of Medicine, Department of Medicine, Box 689, 601 Elmwood Ave., Rochester, NY 14642. Phone: (716) 275-5871. Fax: (716)
442-9328. E-mail: rrose{at}medicine.rochester.edu.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|